• +1-646-491-9876
    • +91-20-67278686

    Search

    Sepsis - Pipeline Review, H1 2017

    Sepsis - Pipeline Review, H1 2017

    • Report Code ID: RW0001689413
    • Category Healthcare
    • No. of Pages 278
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2017, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

    Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 6, 1, 60, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 7 molecules, respectively.

    Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 6
    List of Figures 8
    Introduction 9
    Publisher Report Coverage 9
    Sepsis - Overview 10
    Sepsis - Therapeutics Development 11
    Pipeline Overview 11
    Pipeline by Companies 12
    Pipeline by Universities/Institutes 17
    Products under Development by Companies 20
    Products under Development by Universities/Institutes 25
    Sepsis - Therapeutics Assessment 28
    Assessment by Target 28
    Assessment by Mechanism of Action 31
    Assessment by Route of Administration 34
    Assessment by Molecule Type 36
    Sepsis - Companies Involved in Therapeutics Development 38
    Adrenomed AG 38
    Altor BioScience Corp 38
    Am-Pharma BV 39
    Arch Biopartners Inc. 39
    Aridis Pharmaceuticals LLC 40
    Asahi Kasei Pharma Corp 40
    Astellas Pharma Inc 41
    Batu Biologics Inc 41
    Biomedica Management Corp 42
    Boehringer Ingelheim GmbH 42
    Bristol-Myers Squibb Company 43
    Cell2B Advanced Therapeutics SA 43
    Chiome Bioscience Inc 44
    Cilian AG 44
    Dr. Franz Kohler Chemie GmbH 45
    Endacea Inc 45
    Evec Inc 46
    Ferring International Center SA 46
    Huons Co Ltd 47
    Immune Response BioPharma Inc 47
    Immunethep SA 48
    InflaRx GmbH 48
    Inotrem SA 49
    Integrated BioTherapeutics Inc 49
    Lead Discovery Center GmbH 50
    Leading BioSciences Inc 50
    Lixte Biotechnology Holdings Inc 51
    Merck & Co Inc 51
    Navigen Pharmaceuticals Inc 52
    Nohla Therapeutics Inc 52
    Novartis AG 53
    OncoImmune Inc 53
    Ono Pharmaceutical Co Ltd 54
    Opsona Therapeutics Ltd 54
    Peptinov SAS 55
    ProThera Biologics Inc 55
    Ra Pharmaceuticals Inc 56
    Recce Ltd 56
    Revimmune LLC 57
    Ribomic Inc 57
    SciClone Pharmaceuticals Inc 58
    SetLance srl 58
    Shionogi & Co Ltd 59
    Silence Therapeutics Plc 59
    SK Biopharmaceuticals Co Ltd 60
    Spider Biotech 60
    Stemedica Cell Technologies Inc 61
    Syntiron LLC 61
    TaiRx Inc 62
    Takeda Pharmaceutical Company Ltd 62
    Therakind Ltd 63
    Therashock LLC 63
    TiGenix NV 64
    VBS Pharmaceuticals 64
    Sepsis - Drug Profiles 65
    (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile 65
    3K3A-APC - Drug Profile 66
    7-H9 - Drug Profile 68
    AB-012 - Drug Profile 69
    AB-022 - Drug Profile 70
    AcPepA - Drug Profile 71
    adrecizumab - Drug Profile 72
    ALT-836 - Drug Profile 73
    AM-12 - Drug Profile 75
    AM/AMBP-1 - Drug Profile 76
    Aspidasept - Drug Profile 77
    Atu-111 - Drug Profile 78
    AyuV-25 - Drug Profile 79
    BC-1215 - Drug Profile 80
    BI-113823 - Drug Profile 81
    Biologic to Inhibit PD-L1 for Immunology - Drug Profile 82
    BMS-936559 - Drug Profile 83
    BMS-986189 - Drug Profile 86
    BRL-44408 - Drug Profile 87
    C-23 - Drug Profile 88
    CAR Peptide - Drug Profile 89
    cefiderocol - Drug Profile 90
    ceftaroline fosamil - Drug Profile 92
    Cell Therapy for Sepsis - Drug Profile 95
    Cx-611 - Drug Profile 96
    CYT-107 - Drug Profile 100
    Drug for Sepsis and Septic Shock - Drug Profile 103
    Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 104
    EC-18 - Drug Profile 105
    Escherichia coli vaccine - Drug Profile 107
    ethinylestradiol - Drug Profile 108
    EV-007156 - Drug Profile 109
    Gamma-PN - Drug Profile 110
    Glyco-23 - Drug Profile 111
    HBN-1 - Drug Profile 112
    HBN-3 - Drug Profile 113
    HBN-4 - Drug Profile 114
    HU-003 - Drug Profile 115
    IFX-1 - Drug Profile 116
    ImmStem - Drug Profile 118
    ImmuneSafe - Drug Profile 119
    IMT-504 - Drug Profile 120
    IR-999 - Drug Profile 122
    Klebsiella pneumoniae vaccine - Drug Profile 123
    L-257 - Drug Profile 124
    L-971 - Drug Profile 125
    LB-100 - Drug Profile 127
    lodelcizumab - Drug Profile 130
    M-33 - Drug Profile 131
    M-6229 - Drug Profile 133
    melatonin - Drug Profile 134
    Metablok - Drug Profile 135
    Monoclonal Antibodies for Sepsis - Drug Profile 136
    Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile 137
    Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 138
    Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 139
    Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 140
    Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile 141
    Monoclonal Antibody to Inhibit Semaphorin 3A for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile 142
    Motrem - Drug Profile 143
    MSP-68 - Drug Profile 144
    NAV-838 - Drug Profile 145
    nivolumab - Drug Profile 146
    NOXD-21 - Drug Profile 185
    OPN-305 - Drug Profile 186
    OTP-300 - Drug Profile 189
    OTP-602 - Drug Profile 190
    Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 191
    physostigmine salicylate - Drug Profile 192
    pneumococcal vaccine - Drug Profile 193
    PNV-1 - Drug Profile 194
    Protein to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 195
    Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 196
    R-190 - Drug Profile 198
    RA-101295 - Drug Profile 200
    RBM-005 - Drug Profile 201
    RECCE-327 - Drug Profile 202
    Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile 204
    Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile 205
    Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 209
    Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 210
    Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 211
    Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile 212
    Recombinant Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile 213
    Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile 214
    Recombinant Protein to Target Von Willebrand Factor Type A1 Domain for Sepsis - Drug Profile 215
    SAN-101 - Drug Profile 216
    SB-056 - Drug Profile 217
    selepressin - Drug Profile 218
    Slit-2N - Drug Profile 219
    Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 221
    Small Molecule to HDAC6 for Sepsis - Drug Profile 222
    Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 223
    Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 224
    Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 225
    Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 226
    Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 227
    Small Molecules to Inhibit Sialidase for Bacterial Sepsis - Drug Profile 228
    SP-14 - Drug Profile 229
    SP-9 - Drug Profile 230
    Staphylococcus aureus (multivalent) vaccine - Drug Profile 231
    Stem Cell Therapy for Autoimmune Diseases - Drug Profile 232
    Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 234
    Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 240
    Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 241
    Synthetic Peptides for Infectious Disease - Drug Profile 242
    Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile 243
    Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 244
    TF-0003 - Drug Profile 245
    thrombomodulin alfa - Drug Profile 246
    thymalfasin - Drug Profile 248
    tosatoxumab - Drug Profile 249
    tranexamic acid - Drug Profile 251
    TRX-306 - Drug Profile 253
    vancomycin hydrochloride - Drug Profile 254
    Yersinia pestis vaccine - Drug Profile 255
    Sepsis - Dormant Projects 256
    Sepsis - Discontinued Products 260
    Sepsis - Product Development Milestones 262
    Featured News & Press Releases 262
    Appendix 269
    Methodology 269
    Coverage 269
    Secondary Research 269
    Primary Research 269
    Expert Panel Validation 269
    Contact Us 269
    Disclaimer 270

    List of Tables

    Number of Products under Development for Sepsis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Companies, H1 2017 (Contd..3), H1 2017
    Products under Development by Companies, H1 2017 (Contd..4), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Sepsis - Pipeline by Adrenomed AG, H1 2017
    Sepsis - Pipeline by Altor BioScience Corp, H1 2017
    Sepsis - Pipeline by Am-Pharma BV, H1 2017
    Sepsis - Pipeline by Arch Biopartners Inc., H1 2017
    Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
    Sepsis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
    Sepsis - Pipeline by Astellas Pharma Inc, H1 2017
    Sepsis - Pipeline by Batu Biologics Inc, H1 2017
    Sepsis - Pipeline by Biomedica Management Corp, H1 2017
    Sepsis - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Sepsis - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
    Sepsis - Pipeline by Chiome Bioscience Inc, H1 2017
    Sepsis - Pipeline by Cilian AG, H1 2017
    Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H1 2017
    Sepsis - Pipeline by Endacea Inc, H1 2017
    Sepsis - Pipeline by Evec Inc, H1 2017
    Sepsis - Pipeline by Ferring International Center SA, H1 2017
    Sepsis - Pipeline by Huons Co Ltd, H1 2017
    Sepsis - Pipeline by Immune Response BioPharma Inc, H1 2017
    Sepsis - Pipeline by Immunethep SA, H1 2017
    Sepsis - Pipeline by InflaRx GmbH, H1 2017
    Sepsis - Pipeline by Inotrem SA, H1 2017
    Sepsis - Pipeline by Integrated BioTherapeutics Inc, H1 2017
    Sepsis - Pipeline by Lead Discovery Center GmbH, H1 2017
    Sepsis - Pipeline by Leading BioSciences Inc, H1 2017
    Sepsis - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
    Sepsis - Pipeline by Merck & Co Inc, H1 2017
    Sepsis - Pipeline by Navigen Pharmaceuticals Inc, H1 2017
    Sepsis - Pipeline by Nohla Therapeutics Inc, H1 2017
    Sepsis - Pipeline by Novartis AG, H1 2017
    Sepsis - Pipeline by OncoImmune Inc, H1 2017
    Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Sepsis - Pipeline by Opsona Therapeutics Ltd, H1 2017
    Sepsis - Pipeline by Peptinov SAS, H1 2017
    Sepsis - Pipeline by ProThera Biologics Inc, H1 2017
    Sepsis - Pipeline by Ra Pharmaceuticals Inc, H1 2017
    Sepsis - Pipeline by Recce Ltd, H1 2017
    Sepsis - Pipeline by Revimmune LLC, H1 2017
    Sepsis - Pipeline by Ribomic Inc, H1 2017
    Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H1 2017
    Sepsis - Pipeline by SetLance srl, H1 2017
    Sepsis - Pipeline by Shionogi & Co Ltd, H1 2017
    Sepsis - Pipeline by Silence Therapeutics Plc, H1 2017
    Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
    Sepsis - Pipeline by Spider Biotech, H1 2017
    Sepsis - Pipeline by Stemedica Cell Technologies Inc, H1 2017
    Sepsis - Pipeline by Syntiron LLC, H1 2017
    Sepsis - Pipeline by TaiRx Inc, H1 2017
    Sepsis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Sepsis - Pipeline by Therakind Ltd, H1 2017
    Sepsis - Pipeline by Therashock LLC, H1 2017
    Sepsis - Pipeline by TiGenix NV, H1 2017
    Sepsis - Pipeline by VBS Pharmaceuticals, H1 2017
    Sepsis - Dormant Projects, H1 2017
    Sepsis - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Sepsis - Dormant Projects, H1 2017 (Contd..2), H1 2017
    Sepsis - Dormant Projects, H1 2017 (Contd..3), H1 2017
    Sepsis - Discontinued Products, H1 2017
    Sepsis - Discontinued Products, H1 2017 (Contd..1), H1 2017

    List of Figures

    Number of Products under Development for Sepsis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Adrenomed AG
    Altor BioScience Corp
    Am-Pharma BV
    Arch Biopartners Inc.
    Aridis Pharmaceuticals LLC
    Asahi Kasei Pharma Corp
    Astellas Pharma Inc
    Batu Biologics Inc
    Biomedica Management Corp
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Cell2B Advanced Therapeutics SA
    Chiome Bioscience Inc
    Cilian AG
    Dr. Franz Kohler Chemie GmbH
    Endacea Inc
    Evec Inc
    Ferring International Center SA
    Huons Co Ltd
    Immune Response BioPharma Inc
    Immunethep SA
    InflaRx GmbH
    Inotrem SA
    Integrated BioTherapeutics Inc
    Lead Discovery Center GmbH
    Leading BioSciences Inc
    Lixte Biotechnology Holdings Inc
    Merck & Co Inc
    Navigen Pharmaceuticals Inc
    Nohla Therapeutics Inc
    Novartis AG
    OncoImmune Inc
    Ono Pharmaceutical Co Ltd
    Opsona Therapeutics Ltd
    Peptinov SAS
    ProThera Biologics Inc
    Ra Pharmaceuticals Inc
    Recce Ltd
    Revimmune LLC
    Ribomic Inc
    SciClone Pharmaceuticals Inc
    SetLance srl
    Shionogi & Co Ltd
    Silence Therapeutics Plc
    SK Biopharmaceuticals Co Ltd
    Spider Biotech
    Stemedica Cell Technologies Inc
    Syntiron LLC
    TaiRx Inc
    Takeda Pharmaceutical Company Ltd
    Therakind Ltd
    Therashock LLC
    TiGenix NV
    VBS Pharmaceuticals

    Request for Sample

    Report Url http://www.reportsweb.com//sepsis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//sepsis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//sepsis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments